<DOC>
	<DOCNO>NCT02842125</DOCNO>
	<brief_summary>This Phase 1 study combination Ad-p53 administer intra-arterially combination oral metronomic capecitabine patient unresectable , refractory liver metastasis colorectal carcinoma ( CRC ) solid tumor , include primary hepatocellular carcinoma ( HCC ) . This safety study standard 3+3 design . The Maximum Tolerated Dose ( MTD ) determine well general safety preliminary efficacy use RECIST 1.1 Immune-Related Response Criteria . CEA level also follow .</brief_summary>
	<brief_title>Safety Efficacy Intra-Arterial Ad-p53 Liver Metastases Solid Tumors</brief_title>
	<detailed_description>This Phase 1 study combination Ad-p53 administer intra-arterially combination oral metronomic capecitabine patient unresectable , refractory liver metastasis colorectal carcinoma ( CRC ) solid tumor , include primary hepatocellular carcinoma ( HCC ) . This safety study standard 3+3 design , dose follow initial cohort determine MTD DLT criterion well safety tolerance . Patients follow adverse event preliminary efficacy . The Maximum Tolerated dose ( MTD ) determine well general safety preliminary efficacy use RECIST 1.1 Immune-Related Response Criteria . CEA level also follow . Biomarker test archival fresh tissue perform study . Patients undergo maximum 2 8-week cycle , scan every 8 week . No additional biopsy plan follow Screening . Enrollment 24 patient .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Signed informed consent 2 . Male female 3 . Histologically cytologically confirm solid tumor hepatocellular carcinoma know disease progression . 4 . Subjects measurable CTevidence liver metastases liver lesion treatable surgical resection local ablation consultation hepatobiliary specialist . 5 . Age ≥18 6 . ECOG Performance Status 0 1 7 . Either brain metastasis irradiate stable brain metastasis . 8 . Life expectancy ≥ 5 month 9 . No prior autologous allogeneic organ tissue transplantation 10 . PT/international normalized ratio ( INR ) ≤ ULN ; aPTT ≤ ULN 11 . New York Heart Association classification &lt; III 12 . ANC ≥ 1500 cells/mm3 13 . Platelet count ≥100,000 cells/mm3 14 . Hemoglobin ≥10.0 g/dL 15 . Creatinine &lt; 2.0 mg/dL creatinine clearance ≥ 60 mL/min 16 . Total bilirubin &lt; 1.5 x ULN 17 . AST ALT &lt; 3.0 x ULN 18 . Negative pregnancy test woman childbearing potential 19 . Fertile patient must use effective contraception 20 . No nonapproved investigational agent procedure £4 week study entry 21 . Favorable tumor p53 biomarker profile Adp53 efficacy define either wildtype p53 gene configuration £20 % p53 positive cell immunohistochemistry 22 . ChildPugh score must A B7 23 . Patients HCC must undetectable viral load Hepatitis B C. 24 . Patients HCC must recently treat antiviral . 1 . Subjects must candidate hepatic surgery locoregional therapy liver tumor curative intent . 2 . Liver tumor must estimate invade approximately onethird liver . 3 . Liver tumordirected therapy , hepatic surgery , antibodybased therapy , immunotherapy must perform &lt; 28 day , chemotherapy &lt; 21 day , target small molecule therapy hormonal therapy &lt; 14 day prior enrollment . Nor radiation tumor site last 4 week . 4 . No macroscopic intravascular invasion tumor main portal vein , hepatic vein vena cava . 5 . Chronic liver dysfunction prior development liver metastasis ( ChildPugh C great ) 6 . Active alcohol dependence 7 . Neuropathy ( ≥ grade 2 NCICTC ) 8 . History allergic reaction component treatment 9 . Prior malignancy within 2 year except nonmelanoma skin cancer , carcinoma situ breast , oral cavity cervix . 10 . Severe , active comorbidity Active clinically serious infection require intravenous antibiotic time study entry ( CTCAE Grade 2 ) Hepatic insufficiency due tumor result clinical jaundice bilirubin &gt; 1.5 x ULN and/or coagulation defect Thrombotic embolic event within last 6 month include portal vein thrombosis Must require concomitant treatment anticoagulant QTcb &gt; 470 m Bleeding evidence history clinically significant bleed diathesis coagulopathy within last 3 month Uncontrolled hypertension antihypertensive medication ( systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 95 mmHg ) Must diagnose autoimmune disease immunosuppressed Patients nonhepatocellular carcinoma must acute chronic hepatitis B hepatitis C infection Known human immunodeficiency virus ( HIV ) Severe bleeding , hemoptysis , gastrointestinal hemorrhage , CNS bleed Clinically significant hemorrhage vaginal bleeding last 6 month 11 . Chronic treatment 6 month systemic corticosteroid dose 10 mg ( prednisolone equivalent ) study entry 12 . Psychological , familial , sociological geographical condition opinion investigator would permit study followup compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>solid tumor</keyword>
	<keyword>hepatocellular</keyword>
	<keyword>Ad-P53</keyword>
	<keyword>metastatic</keyword>
	<keyword>capecitabine</keyword>
</DOC>